Form 4: Cue Biopharma Executive Lucinda Warren Acquires 350,000 Stock Options

Lucinda Warren, Chief Business Officer of Cue Biopharma, Inc., reports the acquisition of 350,000 stock options exercisable beginning March 3, 2025.

Summary

• Lucinda Warren, the Chief Business Officer of Cue Biopharma, Inc., filed a Form 4 on September 5, 2024.
• The form reports a transaction that occurred on September 3, 2024, where Ms. Warren acquired 350,000 stock options.
• These options have an exercise price of $0.66.
• The options become exercisable in four equal semi-annual installments starting on March 3, 2025.
• The expiration date for these options is September 2, 2034.
• Following the reported transaction, Ms. Warren directly owns 350,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating an executive's stock option grant. While stock option grants can be seen as a positive incentive, the filing itself is simply a reporting requirement.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates changes in the beneficial ownership of securities by an officer of Cue Biopharma.

Stakeholder Impact

• The acquisition of stock options by a company executive can potentially align the executive's interests with those of the shareholders, as the value of the options is tied to the company's stock performance.

Key Dates